In late 2010, Merck announced that it had acquired SmartCells, a small Massachusetts-based company that is developing a smart insulin product aptly named SmartInsulin...
Diabetes Drug News
Diabetes Drugs are responsible for helping to decrease blood sugar levels so that you can try to stay in a healthier range and help avoid serious complications.
Metformin Insulin SGLT-2 GLP-1 DPP-4 Combo drugs Sulfonylureas TZDs
45 readers recommended
41 readers recommended
People with diabetes are at significantly increased risk for kidney impairment or kidney failure. Kidney disease can complicate the treatment of type 2 diabetes because...
47 readers recommended
Type 1s and GLP-1s? diaTribe Editor-In-Chief Kelly Close tries Victoza and shares her remarkable results.
63 readers recommended
Earlier this month, Eli Lilly and the German pharmaceutical Boehringer Ingelheim (BI) announced a major partnership to co-develop and co-commercialize several of their...
48 readers recommended
Can Victoza help people with type 1 diabetes? See what Novo Nordisk has to say inside.
36 readers recommended
In a major setback for MannKind Corporation ’s inhalable insulin therapy, Afrezza, the FDA is requiring the company to conduct two additional clinical trials of the...
31 readers recommended
Novo Nordisk’s “next-generation” basal insulin degludec. Novo Nordisk has released promising data from a 7,000-participant clinical trial for its next-generation basal...
27 readers recommended
Just in time for the New Year, Kelly reveals good news on obesity therapies and insulin delivery devices.
46 readers recommended
Novo Nordisk’s once daily GLP-1 agonist Victoza (above) provided slightly better improvements in blood glucose control than Amylin/Eli Lilly/ Alkermes’s once weekly GLP-...
37 readers recommended
A thorough review and “how-to” on the drug Symlin (Amylin’s pramlintide).
38 readers recommended
Last week, in a surprise and, in our view, disappointing move, the FDA decided to not approve Bydureon, a once-weekly GLP-1 agonist, for use in the United States despite...
44 readers recommended
For type 2 patients, the use of GLP-1 agonists (such as Victoza and Byetta ) can often lead to significant improvements in blood glucose control and weight loss with...
28 readers recommended
A girl can dream, right? (...of cures and new insulins...)
43 readers recommended
David Simmons, President and General Manager of Pfizer’s Established Products Business Unit, and Kiran Mazumdar-Shaw, Chairman and Managing Director of Biocon, shake...
26 readers recommended
Kelly muses on the future of GLP-1 agonists and bariatric surgery.
22 readers recommended
Kelly’s take on the maddeningly slow FDA approval process and why things are probably getting better.
29 readers recommended
Kerri Morrone Sparling reflects on the true meaning of ‘need’ in the global diabetes community…
37 readers recommended
Novo Nordisk’s Head of China Ron Christie divulges details on the state of diabetes care in the world’s most populous nation.
39 readers recommended
As we have previously written, Vivus’ weight loss drug Qnexa is up for approval in the US in April of this year. Encouragingly, Vivus announced recently that, if...
29 readers recommended
Late last year, we found out about a new drug being developed by Reata Pharmaceuticals for the treatment of chronic kidney disease (CKD), a disorder that occurs more...